A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

Under the deal, Sun Pharma will buy the outstanding shares ... 66% to Checkpoint’s closing share price last Friday, the Indian pharmaceutical giant said in a statement on Monday.

Domestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the ...

Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...

New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...

A new study reveals that generic drugs made in India are linked to a significantly higher number of severe adverse events, ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.

Indian pharma CDMOs remain resilient, continuing to thrive due to favorable global factors. The B&K Securities report ...